EGRX Eagle Pharmaceuticals Inc

Price (delayed)

$4.61

Market cap

$59.87M

P/E Ratio

5.01

Dividend/share

N/A

EPS

$0.92

Enterprise value

$114.71M

Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements ...

Highlights

Eagle Pharmaceuticals's quick ratio has increased by 35% YoY and by 8% from the previous quarter

The company's equity rose by 6% YoY and by 3.8% QoQ

Eagle Pharmaceuticals's debt has increased by 41% YoY but it has decreased by 8% QoQ

Eagle Pharmaceuticals's gross margin has decreased by 5% YoY but it has increased by 2% from the previous quarter

The EPS has contracted by 50% YoY

The net income has declined by 48% year-on-year

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.eagleus.com

Peers: JNJ TEVA NVS AMGN

Key stats

What are the main financial stats of EGRX

Market

Shares outstanding

12.99M

Market cap

$59.87M

Enterprise value

$114.71M

Valuations

Price to earnings (P/E)

5.01

Price to book (P/B)

0.24

Price to sales (P/S)

0.23

EV/EBIT

3.25

EV/EBITDA

2.01

EV/Sales

0.45

Earnings

Revenue

$257.55M

EBIT

$35.26M

EBITDA

$57.18M

Free cash flow

-$9.39M

Per share

EPS

$0.92

Free cash flow per share

-$0.72

Book value per share

$19.25

Revenue per share

$19.67

TBVPS

$19.28

Balance sheet

Total assets

$404.82M

Total liabilities

$152.78M

Debt

$70.19M

Equity

$252.04M

Working capital

$100.62M

Liquidity

Debt to equity

0.28

Current ratio

2.16

Quick ratio

1.51

Net debt/EBITDA

0.96

Margins

EBITDA margin

22.2%

Gross margin

69.8%

Net margin

4.6%

Operating margin

15.9%

Efficiency

Return on assets

Return on equity

Return on invested capital

19.3%

Return on capital employed

11.1%

Return on sales

13.7%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EGRX stock price

How has the Eagle Pharmaceuticals stock price performed over time

Intraday

2.9%

1 week

0.44%

1 month

-16.18%

1 year

-83.77%

YTD

-11.85%

QTD

-12.02%

Financial performance

How have Eagle Pharmaceuticals's revenue and profit performed over time

Revenue

$257.55M

Gross profit

$179.88M

Operating income

$41.01M

Net income

$11.95M

Gross margin

69.8%

Net margin

4.6%

The net income has declined by 48% year-on-year

Eagle Pharmaceuticals's net margin has decreased by 45% YoY

Eagle Pharmaceuticals's operating income has decreased by 29% YoY but it has increased by 25% QoQ

The operating margin is up by 29% since the previous quarter but it has declined by 25% year-on-year

Growth

What is Eagle Pharmaceuticals's growth rate over time

Valuation

What is Eagle Pharmaceuticals stock price valuation

P/E

5.01

P/B

0.24

P/S

0.23

EV/EBIT

3.25

EV/EBITDA

2.01

EV/Sales

0.45

The EPS has contracted by 50% YoY

EGRX's P/B is 92% below its 5-year quarterly average of 3.0 and 83% below its last 4 quarters average of 1.4

The company's equity rose by 6% YoY and by 3.8% QoQ

EGRX's price to sales (P/S) is 92% lower than its 5-year quarterly average of 2.8 and 81% lower than its last 4 quarters average of 1.2

The company's revenue fell by 5% YoY and by 3.6% QoQ

Efficiency

How efficient is Eagle Pharmaceuticals business performance

The ROS has soared by 90% from the previous quarter but it has contracted by 12% YoY

EGRX's return on invested capital has surged by 61% since the previous quarter but it has dropped by 55% year-on-year

Eagle Pharmaceuticals's ROA has plunged by 60% YoY

Eagle Pharmaceuticals's return on equity has shrunk by 55% YoY

Dividends

What is EGRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EGRX.

Financial health

How did Eagle Pharmaceuticals financials performed over time

Eagle Pharmaceuticals's total assets is 165% higher than its total liabilities

Eagle Pharmaceuticals's quick ratio has increased by 35% YoY and by 8% from the previous quarter

EGRX's current ratio is up by 21% YoY and by 10% QoQ

Eagle Pharmaceuticals's debt is 72% lower than its equity

Eagle Pharmaceuticals's debt has increased by 41% YoY but it has decreased by 8% QoQ

Eagle Pharmaceuticals's debt to equity has increased by 33% YoY but it has decreased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.